Mallinckrodt Pharmaceuticals leaders celebrated the opening of a new building addition to the nearly 150-year-old original plant site north of downtown St. Louis with a ribbon cutting on Friday, April 10. The $12.25 million addition is an investment that will help the company to continue its mission of managing complexity and improving lives. The addition will make the site’s manufacturing process more efficient, resulting in quicker turnaround time to get medicines to patients who need them.
Front row, from left: Frank Scholz, Senior Vice President of Global Operations; Mark Trudeau, President and CEO; Dexter Evans, St. Louis Plant Senior Site Director; and Pete Fitzgerald, St. Louis Plant Focus Factory Manager.
Back row, from left: Matt Harbaugh, Senior Vice President and Chief Financial Officer; Meredith Fischer, Senior Vice President, Communications and Public Affairs; Peter Edwards, Senior Vice President and General Counsel; Hugh O’Neill, Senior Vice President and President of U.S. Specialty Pharmaceuticals; Sandy Hatten, Senior Vice President of Quality; Gary Phillips, Senior Vice President and Chief Strategy Officer; and Ian Watkins, Senior Vice President and Chief Human Resources Officer.